AbCellera Biologics (ABCL) EBIT (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of EBIT data on file, last reported at -$57.5 million in Q1 2026.

• Quarterly EBIT rose 8.2% year-over-year to -$57.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.0 million (up 34.28% YoY) and the FY2025 annual result came in at -$217.1 million, up 31.03% from the prior year.
• EBIT slipped to -$57.5 million in Q1 2026, from -$28.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $225.0 million in Q1 2022 to a low of -$93.7 million in Q3 2024.
• A 5-year average of -$35.9 million and a median of -$54.9 million in 2024 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT jumped 234.31% — and 2023, when it slumped 512.07%.
• Tracing ABCL's EBIT over 5 years: stood at -$37.8 million in 2022, then slumped by 74.85% to -$66.1 million in 2023, then declined by 10.15% to -$72.8 million in 2024, then soared by 60.71% to -$28.6 million in 2025, then slumped by 101.24% to -$57.5 million in 2026.
• The last three EBIT figures came in at -$57.5 million (Q1 2026), -$28.6 million (Q4 2025), and -$76.3 million (Q3 2025), per Business Quant data.